Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term antiarrhythmic therapy with cibenzoline.

S M Mohiuddin1, D E Hilleman, D Esterbrooks

  • 1Drug Evaluation Unit, Creighton University School of Medicine, Omaha, NE 68131.

Journal of Clinical Pharmacology
|May 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Effectiveness and Safety of Imeglimin in Type 2 Diabetes: Prospective Multi-Center Study in Bangladesh.

Diabetes, metabolic syndrome and obesity : targets and therapy·2026
Same author

Approach to Diagnosis and Management of Polycystic Ovary Syndrome in Bangladesh: A Nationwide Cross-Sectional Survey of Physicians.

Cureus·2025
Same author

Effectiveness of ertugliflozin during Ramadan fasting in patients with type 2 diabetes mellitus: a real-world study (ErtuRamadan study).

Frontiers in endocrinology·2025
Same author

The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes.

Drugs of today (Barcelona, Spain : 1998)·2010
Same author

Surgical and visual outcomes for posterior polar cataract.

The British journal of ophthalmology·2008
Same author

Dofetilide: A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter.

Drugs of today (Barcelona, Spain : 1998)·2003
Same journal

FDA Gene Therapy Approvals (1998-2025): Current Status, Regulatory Evolution, and Future Directions.

Journal of clinical pharmacology·2026
Same journal

Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

Journal of clinical pharmacology·2026
Same journal

New Insights into Genetic Polymorphisms Influencing the Therapeutic Efficacy and Toxicity of Rivaroxaban.

Journal of clinical pharmacology·2026
Same journal

Physiologically Based Pharmacokinetic Modeling to Predict the Pharmacokinetics of Sacubitril/Valsartan in the Elderly with Renal or Hepatic Impairment Population.

Journal of clinical pharmacology·2026
Same journal

The Journal of Clinical Pharmacology: 65 Years of History.

Journal of clinical pharmacology·2026
Same journal

Decoupling CAR-T Expansion, Conversion, and Decay Timing: Physiologically Aligned Semi-Mechanistic Modeling With Smooth Gating and a Cauchy Likelihood Residual Model.

Journal of clinical pharmacology·2026
See all related articles

Cibenzoline effectively treats chronic ventricular arrhythmias in the short term for most patients. Long-term efficacy requires periodic assessment, as some patients may lose arrhythmia control or experience adverse effects.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic ventricular arrhythmias pose a significant clinical challenge.
  • Effective and safe antiarrhythmic therapies are crucial for patient management.

Purpose of the Study:

  • To evaluate the long-term efficacy and safety of cibenzoline in patients with chronic ventricular arrhythmias.
  • To assess the impact of cibenzoline on left ventricular function.

Main Methods:

  • Single-blind, placebo-controlled study involving 19 patients.
  • Dose titration followed by long-term therapy assessment.
  • Echocardiographic evaluation of left ventricular function.

Main Results:

  • Short-term efficacy achieved in 74% of patients, with significant reductions in premature ventricular complexes (PVCs) and ventricular tachycardia (VT).

Related Experiment Videos

  • Long-term efficacy was maintained in 36% of initial responders.
  • Adverse effects occurred in 37% of patients, with only one discontinuation due to side effects.
  • No deleterious effect on overall left ventricular function; improvement noted in patients with pre-existing dysfunction.

    • Conclusions:

    • Cibenzoline is effective for short-term management of chronic ventricular arrhythmias.
    • Long-term use necessitates ongoing monitoring for sustained efficacy and potential adverse events.
    • Cibenzoline appears safe for patients with compensated left ventricular dysfunction.